Clinical trials: Acute Migraine
Migraine
A Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study of Elismetrep (K-304) in the Treatment of Migraine
This is a double-blind, randomized, multicenter, outpatient evaluation of the safety and efficacy of elismetrep as compared to placebo in the acute treatment of migraine.
- Trial name
- NCT06848075
- Testing
- Elismetrep (K-304) 2 mg, Elismetrep (K-304) 5 mg, Elismetrep (K-304) 10 mg
- Where
- 66 sites in United States
- Volunteers
- 431 people
- Sponsor
- TriGemX Bio, Inc.
Migraine
Greater Occipital Nerve Block With Bupivacaine for Acute Migraine
This is a randomized, sham-controlled study of greater occipital nerve block (GONB) using bupivacaine 0.5% for emergency department patients with acute migraine.
- Trial name
- NCT02665273
- Testing
- Greater occipital nerve block, Bupivacaine
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Montefiore Medical Center
Acute Migraine
Safety and Efficacy Trial of BHV3000 (Rimegepant) 75 mg for the Acute Treatment of Migraine
This trial is to determine whether BHV3000 (rimegepant) 75mg is safe and effictive as a treatment for acute migraine in Chinese and Korean patients
- Trial name
- NCT04574362
- Testing
- Rimegepant
- Where
- 90 sites in China, South Korea
- Volunteers
- 1,648 people
- Sponsor
- Pfizer
Migraine Headache
MK0462 5 mg, Sumatriptan 50 mg, and Placebo Comparison Study (0462-029)
A study to compare rizatriptan (MK0462) 5 mg by mouth (p.o.) and sumatriptan 50 mg p.o. for the acute treatment of a migraine attack.
- Trial name
- NCT00897104
- Testing
- rizatriptan benzoate (MK0462), Comparator: sumatriptan
- Volunteers
- 933 people
- Sponsor
- Organon and Co
Migraine Disorders
A Study of Lasmiditan in Participants With Migraine
The purpose of this study is to measure how much of the drug gets into the blood stream and how long it takes the body to get rid of it during an acute migraine attack and also during the time between acute migraine attacks.
- Trial name
- NCT03247790
- Testing
- Lasmiditan
- Where
- 3 sites in United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Migraine
Pharmacokinetics & Safety of Cambia® in Migraine With or Without Aura in 12-17 Year Olds
Study Objectives: 1. The primary objective is to characterize the pharmacokinetics of a single oral administration of 50 mg Cambia in pediatric subjects, ages 12-17 years with a diagnosis of episodic migraine with or without…
- Trial name
- NCT02287376
- Testing
- Diclofenac Potassium for Oral Solution
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Depomed
Migraine
An Exploratory Prospective Trial of Rescue Acupuncture for the Treatment of Acute Migraine
This will be an exploratory observational trial of rescue acupuncture for the treatment of acute migraine in military beneficiaries to gain information to inform the power analysis of a larger, more definitive trial.
- Trial name
- NCT02764996
- Testing
- Acupuncture
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Mike O'Callaghan Military Hospital
Migraine Disorders
Reliability of Rimegepant or Triptans for the Acute Treatment of Migraine
This protocol describes the analysis of the Adelphi Real World (ARW) Migraine Disease Specific Programme(TM) 2022, a cross-sectional study which used both physician and patient surveys to assess the perception of the acute…
- Trial name
- Adelphi DSP (NCT06412965)
- Where
- United States
- Volunteers
- 528 people
- Sponsor
- Pfizer
Migraine
Efficacy and Tolerability of Rimegepant for the Acute Treatment of Migraine in Adults Unsuitable for Triptan Use
This study is being conducted to evaluate the efficacy and tolerability of rimegepant in a population of adults that are unsuitable for triptan medications due to a previous intolerance, lack of efficacy, or contraindication…
- Trial name
- NCT05509400
- Testing
- Rimegepant
- Where
- 93 sites in United States, Australia and 13 more
- Volunteers
- 813 people
- Sponsor
- Pfizer
Migraine
Corticosteroids for Acute Migraine in the Emergency Department
This is an emergency department based randomized trial in which we compare two different treatment for migraine headache. The goal is to decrease the number of headache days during the week after ED discharge.
- Trial name
- NCT02847494
- Testing
- metoclopramide, Dexamethasone, methylprednisolone acetate
- Where
- 2 sites in United States
- Volunteers
- 220 people
- Sponsor
- Montefiore Medical Center
Migraine Headaches
Prochlorperazine Versus Acetaminophen, Aspirin, and Caffeine for the Treatment of Acute Migraine
The objective of this randomized, double blind study is to demonstrate that one dose oral "excedrin migraine" (acetaminophen, aspirin and caffeine) is not inferior when compared to one dose of intravenous prochlorperazine for the…
- Trial name
- Migraine (NCT01629329)
- Testing
- Aspirin, Acetaminophen, Caffeine pills, Prochlorperazine 10mg
- Where
- United States
- Volunteers
- 93 people
- Sponsor
- Albert Einstein Healthcare Network
Migraine Disorders
Study to Evaluate the Efficacy and Safety of Oral Sumatriptan for the Acute Treatment of Migraine in Children and Adolescents
The purpose of this study is to evaluate the efficacy and safety of a range of doses of oral sumatriptan for the acute treatment of migraine in children ages 10 to 17.
- Trial name
- NCT00963937
- Testing
- Sumatriptan 25 mg, Sumatriptan 50 mg
- Where
- 16 sites in Japan
- Volunteers
- 178 people
- Sponsor
- GlaxoSmithKline
Migraine
Study to Evaluate Oral Ubrogepant in the Acute Treatment of Migraine During the Prodrome in Adult Participants
Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine When Administered During the Prodrome
- Trial name
- UBR Prodrome (NCT04492020)
- Testing
- Ubrogepant 100 mg
- Where
- 73 sites in United States
- Volunteers
- 518 people
- Sponsor
- AbbVie
Migraine With or Without Aura
Three Doses of Lasmiditan (50 mg, 100 mg and 200 mg) Compared to Placebo in the Acute Treatment of Migraine
This is a prospective randomized, double-blind, placebo-controlled study in participants with disabling migraine (Migraine Disability Assessment (MIDAS) score ≥ 11).
- Trial name
- SPARTAN (NCT02605174)
- Testing
- Lasmiditan 50 mg, Lasmiditan 100 mg, Lasmiditan 200 mg
- Where
- 95 sites in United States
- Volunteers
- 3,005 people
- Sponsor
- Eli Lilly and Company
Migraine
Acute Treatment of Migraine in Pre-Adolescents: Real-World Analysis of Remote Electrical Neuromodulation (REN)
Migraine is a prevalent neurological disorder that severely impacts both children and adolescents, causing significant disability.
- Trial name
- NCT06138756
- Testing
- Nerivio
- Where
- 2 sites in United States, Israel
- Volunteers
- 293 people
- Sponsor
- Theranica
Migraine
Randomized Trial in Adult Participants With Acute Migraines
The purpose of this study is to test the safety and efficacy of BHV-3500 (zavegepant) versus placebo in the acute treatment of moderate or severe migraine.
- Trial name
- NCT04571060
- Testing
- Zavegepant
- Where
- 94 sites in United States
- Volunteers
- 1,978 people
- Sponsor
- Pfizer
Migraine Disorders
A Study of Combination Product (Sumatriptan Succinate and Naproxen Sodium) in Migraine Subjects Who Report Poor Response or Intolerance to Short Acting Triptans (Study 1 of 2)
This is a randomized, double-blind, placebo-controlled, crossover, two-attack, out-patient, early-intervention evaluation of subjects who have migraine with or without aura and who discontinued use of short acting triptan(s)…
- Trial name
- NCT00383162
- Testing
- Combination Product (sumatriptan succinate / naproxen sodium)
- Where
- 26 sites in United States
- Volunteers
- 173 people
- Sponsor
- GlaxoSmithKline
Migraine
Efficacy and Safety of Intranasal Ketorolac for the Acute Treatment of Migraine
The study evaluates the efficacy and safety of using ketorolac as a nasal spray for the acute treatment of migraine.
- Trial name
- NCT00483717
- Testing
- Ketorolac tromethamine
- Where
- Germany
- Volunteers
- 173 people
- Sponsor
- Egalet Ltd
Migraine, Without Aura
TREXIMET (Formerly Known as TREXIMA) for the Acute Treatment of Probable Migraine (ICHD-II 1.6.1)
This study was designed to determine the efficacy and tolerability of TREXIMET (formerly known as TREXIMA) compared to placebo for the acute treatment of probable migraine, a sub-type of migraine.
- Trial name
- NCT00387881
- Testing
- sumatriptan succinate / naproxen sodium
- Where
- 70 sites in United States
- Volunteers
- 679 people
- Sponsor
- GlaxoSmithKline
Migraine Headache
Study in Participants With Acute Migraines Headaches
This is a Phase 2, multicenter, randomized, double-blind, placebo and active comparator-controlled study of LY2590443 in approximately 200 participants with migraines.
- Trial name
- NCT00804973
- Testing
- LY2590443, Sumatriptan
- Where
- 19 sites in United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company